GenFleet Therapeutics
Developing Novel Drug Candidates

Every new day brings a new medical need today. With the rising population and changing lifestyles, the cases of chronic and acute diseases and conditions are exponentially rising. This is driving the need for innovative solutions worldwide with the expectation of addressing the most critical health conditions efficiently. As a result, pharmaceutical companies in are heavily focusing on leveraging the technologies and new therapeutic approaches to not only control, manage, or treat acute conditions but ultimately cure them. Hence, emerging technologies like big data and AI are playing an active role in accelerating and enhancing the biotech and pharma space to enable organizations to improve drug development and patient care with effective and affordable treatments. At this juncture, several biotech startups are working towards fulfilling the emerging needs in drug and therapeutic development.

Against this backdrop, GenFleet, a clinical-stage biotechnology company,focuses on cutting-edge therapies in oncology and immunology. Founded in 2017, GenFleet Therapeutics has created industry-leading capabilities and expertise in developing novel drug candidates, including small molecules and biologics. The company has over ten programs in development, of which several have entered clinical stages.

GenFleet’s rich pipeline is focused on target innovation and drug development that is driven by biological mechanism research. The company has constructed its proprietary R&D platform based on anin-depth understanding of disease biology, translational medicine, along with the research into the latest biological mechanism of cancer pathways, tumor microenvironment, and human immunoregulation.

This platform caters to unmet medical needs. In addition to this, the firm’s newly introduced DMPK platform facilitates screening and optimization of preclinical candidates through ADME (absorption, distribution, metabolism, and excretion) simulation in the human body and relevant pharmacokinetics studies. This capability elevates success rates of drug discovery and clinical trials from the early stage of R&D programs.

Another key area that GenFleet has penetrated is molecule optimization with its cutting-edge products. From the screening of preclinical candidates to the early-stage process development, the company executes research and analysis of molecule’s structure-activity relationship that allows to prepare goodquality APIs for clinical research and commercial production. To achieve this, GenFleet offers pharmaceutical chemistry, CADD, and AI platforms that enable the team to integrate advanced models like SAR (structure-activity relationship), SPR (structure-property relationship), and CADD (computer-aided drug design) into an R&D platform of synthetic chemistry and computing science. This method serves as a key node linking early discovery and translational medicine. Adding to this, the company also employs multi-layered screening to identify preclinical candidates with active physical and chemical characteristics and superior PK&PD properties for the development of novel molecules to help introduce innovative therapies.

Besides, GenFleet’s new R&D system offers a wide range of functions that includes antibody discovery, identification of drug effects, activity screening, mechanism research, and expression &purification of protein. With its exclusive screening strategy along with antibody engineering, the company develops various types of antibody drugs, aiming for contributions to GenFleet’s balanced matrix of products. These efforts help drive new frontiers in the druggability of small molecules and biologics.

Since its inception, GenFleet’s pipeline has significantly highlighted the exploration of targets and indications without proof of concept while integrating a diverse portfolio of R&D models on the company’s platform. Moving ahead, GenFleet is looking forward to developing additional programs for clinics and transitioning from a clinical-stage biotech company into a commercial-stage biopharmaceutical company in the next three to five years, bringing paramount innovation into the medical and biotechnology space.